-
Lymphovascular Invasion, What Is It?
In this video, Dr. Jay K. Harness explains what exactly lymphovascular invasion is and why it is not a good finding.
Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/#
Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask.
This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
published: 24 May 2012
-
Vascular Invasion
Dr. Margaret Brandwein describes the identification of vascular invasion of thyroid cancer.
Watch the full presentation -
Follow us on Twitter!
@thancfoundation - https://shorturl.at/puwS0
THANC on FB - https://shorturl.at/svNY4
published: 30 Jun 2021
-
Lymphovascular Invasion - CTR Coding Break (June 2023)
The June 2022 CTR Coding Break discusses Lymphovascular Invasion. What is Lymphovascular Invasion exactly? Lymphovascular Invasion is the presence of tumor cells in lymphatic channels and/or blood vessels within the primary tumor noted microscopically by the pathologist. In some cases, the presence or absence of Lymphovascular invasion is used as an indicator of prognosis. The three main objectives of the presentation include: Identifying synonyms for Lymphovascular Invasion, Rules applying codes 0, 8 and 9, and coding Lymphovascular invasion in cases with neoadjuvant therapy.
Synonyms for Lymphovascular invasion include but are not limited to: Angiolymphatic Invasion, Blood Vessel Invasion, Lymph vascular emboli, Lymphatic Invasion, Vascular Invasion & Lymphovascular space invasion. Th...
published: 03 Jul 2023
-
Lymphovascular Invasion - CTR Coding Break (July 2020)
The July 2020 CTR Coding Break addresses the data item Lymphovascular Invasion (LVI). Lymphovascular invasion is defined as the invasion of cancer in the blood vessels and/or lymphatic channels. The main objectives include understanding of code 8 for not applicable, applying codes 2, 3, and 4 for small vessel, large vessel, and both small/large vessel invasion, using the STORE table to code cases treated with neoadjuvant therapy and understanding of code 0 for insitu cases. The presentation works through case examples receiving neoadjuvant therapy and how to use the STORE table to select the accurate code. The first column in the table defines how LVI was reported on the pathology report prior to neoadjuvant therapy, the second column defines how LVI was reported after neoadjuvant therapy ...
published: 24 Jul 2020
-
Vascular Invasion
Copyright 2012 Johns Hopkins University. Artwork by Bona Kim
published: 03 Feb 2012
-
Lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC)
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,[email protected],
https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn
,
,https://plus.google.com/u/0/+AlexandrosGSfakianakis
,
https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ
,
https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Breast Cancer Res Treat. 2018 Jan 27;:
Authors: Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon...
published: 30 Jan 2018
-
Tip-1; Lymphovascular vs. Venous Invasion
Understanding the importance of lymphovascular invasion (LVI) versus venous invasion (VI) in cancer is crucial for accurate diagnosis, staging, and treatment decisions. LVI refers to the infiltration of cancer cells into lymphatics, which increases the risk for lymph node metastasis, while VI specifically involves tumor cells invading venous structures, so increasing the risk of hematogenous distant metastasis.
published: 26 Jun 2023
-
Standardising Tumour Pathology Reporting: Lymphovascular Invasion
Learn more about why we should standardize tumor pathology reporting in this webinar on Lymphovascular Invasion, presented by Drs. Luong and Salas 22 September 2021. This webinar was broadcast as a part of our "Standardizing Tumor Pathology Reporting - Part 2" Series. This seminar is co-sponsored by the ACVP and the Veterinary Cancer Guidelines and Protocols group and is sure to generate some great conversation. Why do we need to standardize? How can we standardize? How can we all be a part of the conversation? What is the role of digital pathology and image analysis in standardization? Join a phenomenal panel of pathologists, clinicians, and computer scientists who are at the cutting edge of standardization.
The Davis-Thompson Foundation is a nonprofit organization for the advancement of...
published: 04 Oct 2021
-
Introduction to Cancer Biology (Part 3): Tissue Invasion and Metastasis
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation provides a closer look at how the EGFR pathway activates and modulates this process of metastasis. This animation is the third part of the series "An Introduction to Cancer Biology".
REFERENCES:
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 200...
published: 27 Oct 2012
-
Lymphovascular invasion (LVI) and non-T4 muscular invasion (non-T4MI) significantly increased the lo
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,[email protected],
https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn
,
,https://plus.google.com/u/0/+AlexandrosGSfakianakis
,
https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ
,
https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Predictors of locoregional recurrence in early stage buccal cancer with pathologically clear surgical margins and negative neck
via Acta Otorrinolaringológica Española
alertIcon.gif
Publication date: Available online 16 March 2018
Source:Acta Otorrinolaringológica Española
Auth...
published: 16 Mar 2018
3:38
Lymphovascular Invasion, What Is It?
In this video, Dr. Jay K. Harness explains what exactly lymphovascular invasion is and why it is not a good finding.
Click Here & Get The 15 Breast Cancer Ques...
In this video, Dr. Jay K. Harness explains what exactly lymphovascular invasion is and why it is not a good finding.
Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/#
Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask.
This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
https://wn.com/Lymphovascular_Invasion,_What_Is_It
In this video, Dr. Jay K. Harness explains what exactly lymphovascular invasion is and why it is not a good finding.
Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/#
Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask.
This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
- published: 24 May 2012
- views: 32781
1:06
Vascular Invasion
Dr. Margaret Brandwein describes the identification of vascular invasion of thyroid cancer.
Watch the full presentation -
Follow us on Twitter!
@thancfounda...
Dr. Margaret Brandwein describes the identification of vascular invasion of thyroid cancer.
Watch the full presentation -
Follow us on Twitter!
@thancfoundation - https://shorturl.at/puwS0
THANC on FB - https://shorturl.at/svNY4
https://wn.com/Vascular_Invasion
Dr. Margaret Brandwein describes the identification of vascular invasion of thyroid cancer.
Watch the full presentation -
Follow us on Twitter!
@thancfoundation - https://shorturl.at/puwS0
THANC on FB - https://shorturl.at/svNY4
- published: 30 Jun 2021
- views: 985
5:51
Lymphovascular Invasion - CTR Coding Break (June 2023)
The June 2022 CTR Coding Break discusses Lymphovascular Invasion. What is Lymphovascular Invasion exactly? Lymphovascular Invasion is the presence of tumor cel...
The June 2022 CTR Coding Break discusses Lymphovascular Invasion. What is Lymphovascular Invasion exactly? Lymphovascular Invasion is the presence of tumor cells in lymphatic channels and/or blood vessels within the primary tumor noted microscopically by the pathologist. In some cases, the presence or absence of Lymphovascular invasion is used as an indicator of prognosis. The three main objectives of the presentation include: Identifying synonyms for Lymphovascular Invasion, Rules applying codes 0, 8 and 9, and coding Lymphovascular invasion in cases with neoadjuvant therapy.
Synonyms for Lymphovascular invasion include but are not limited to: Angiolymphatic Invasion, Blood Vessel Invasion, Lymph vascular emboli, Lymphatic Invasion, Vascular Invasion & Lymphovascular space invasion. This list is located on page 137 of the SEER Program Coding and Staging Manual.
The STORE Manual provides instruction for applying codes 0, 8 and 9. Code 0: indicates LVI is Not Present/Not Identified. STORE instructs to use code 0 when the pathology report indicates there is no lymphovascular invasion. This includes in situ cancers which biologically have no access to lymphatic or vascular channels below the basement membrane. We can apply code 0 for an in situ case even if LVI is not mentioned on the path report. Code 8: Not Applicable is used for Benign/Brain & CNS tumors, Gastrointestinal Stromal Tumors or GISTs and for Heme & Lymphoma histologies. STORE page 148 contains a list of Schema IDs that must be coded to 8 Not Applicable. Code 8 should also be used when your standard setter does not require this item and the state/central registry is not collecting it. Code 9: Unknown/Indeterminate is used when LVI is not documented on the pathology report, there is no microscopic tissue examination from the primary site, the primary site specimen is cytology only, and in cases where the primary site is unknown.
For cases treated with neoadjuvant therapy STORE instructs to refer to the table on page 146 to code the data field. The table should be used based on the results of LVI on the pathology report prior to neoadjuvant therapy (Column 1) and the results of LVI on the pathology report after neoadjuvant therapy (Column 2). Column 3 indicates the code entered into the data field in your registry software. The presentation concludes with 2 case scenarios.
https://wn.com/Lymphovascular_Invasion_Ctr_Coding_Break_(June_2023)
The June 2022 CTR Coding Break discusses Lymphovascular Invasion. What is Lymphovascular Invasion exactly? Lymphovascular Invasion is the presence of tumor cells in lymphatic channels and/or blood vessels within the primary tumor noted microscopically by the pathologist. In some cases, the presence or absence of Lymphovascular invasion is used as an indicator of prognosis. The three main objectives of the presentation include: Identifying synonyms for Lymphovascular Invasion, Rules applying codes 0, 8 and 9, and coding Lymphovascular invasion in cases with neoadjuvant therapy.
Synonyms for Lymphovascular invasion include but are not limited to: Angiolymphatic Invasion, Blood Vessel Invasion, Lymph vascular emboli, Lymphatic Invasion, Vascular Invasion & Lymphovascular space invasion. This list is located on page 137 of the SEER Program Coding and Staging Manual.
The STORE Manual provides instruction for applying codes 0, 8 and 9. Code 0: indicates LVI is Not Present/Not Identified. STORE instructs to use code 0 when the pathology report indicates there is no lymphovascular invasion. This includes in situ cancers which biologically have no access to lymphatic or vascular channels below the basement membrane. We can apply code 0 for an in situ case even if LVI is not mentioned on the path report. Code 8: Not Applicable is used for Benign/Brain & CNS tumors, Gastrointestinal Stromal Tumors or GISTs and for Heme & Lymphoma histologies. STORE page 148 contains a list of Schema IDs that must be coded to 8 Not Applicable. Code 8 should also be used when your standard setter does not require this item and the state/central registry is not collecting it. Code 9: Unknown/Indeterminate is used when LVI is not documented on the pathology report, there is no microscopic tissue examination from the primary site, the primary site specimen is cytology only, and in cases where the primary site is unknown.
For cases treated with neoadjuvant therapy STORE instructs to refer to the table on page 146 to code the data field. The table should be used based on the results of LVI on the pathology report prior to neoadjuvant therapy (Column 1) and the results of LVI on the pathology report after neoadjuvant therapy (Column 2). Column 3 indicates the code entered into the data field in your registry software. The presentation concludes with 2 case scenarios.
- published: 03 Jul 2023
- views: 697
7:11
Lymphovascular Invasion - CTR Coding Break (July 2020)
The July 2020 CTR Coding Break addresses the data item Lymphovascular Invasion (LVI). Lymphovascular invasion is defined as the invasion of cancer in the blood ...
The July 2020 CTR Coding Break addresses the data item Lymphovascular Invasion (LVI). Lymphovascular invasion is defined as the invasion of cancer in the blood vessels and/or lymphatic channels. The main objectives include understanding of code 8 for not applicable, applying codes 2, 3, and 4 for small vessel, large vessel, and both small/large vessel invasion, using the STORE table to code cases treated with neoadjuvant therapy and understanding of code 0 for insitu cases. The presentation works through case examples receiving neoadjuvant therapy and how to use the STORE table to select the accurate code. The first column in the table defines how LVI was reported on the pathology report prior to neoadjuvant therapy, the second column defines how LVI was reported after neoadjuvant therapy resulting in the final code within the third column. Finally, the use of code 0 is discussed for insitu cases. STORE describes code 0 includes cases of purely in situ carcinoma.
For the first time this month, we are making available the presentation as a PDF download if you would like to have it as a reference. Click below to download the PDF version of this month’s CTR Coding Break.
https://drive.google.com/file/d/1RKzDZvQnoRIr47jL9pMJFrbhVk4184JJ/view?usp=sharing
https://wn.com/Lymphovascular_Invasion_Ctr_Coding_Break_(July_2020)
The July 2020 CTR Coding Break addresses the data item Lymphovascular Invasion (LVI). Lymphovascular invasion is defined as the invasion of cancer in the blood vessels and/or lymphatic channels. The main objectives include understanding of code 8 for not applicable, applying codes 2, 3, and 4 for small vessel, large vessel, and both small/large vessel invasion, using the STORE table to code cases treated with neoadjuvant therapy and understanding of code 0 for insitu cases. The presentation works through case examples receiving neoadjuvant therapy and how to use the STORE table to select the accurate code. The first column in the table defines how LVI was reported on the pathology report prior to neoadjuvant therapy, the second column defines how LVI was reported after neoadjuvant therapy resulting in the final code within the third column. Finally, the use of code 0 is discussed for insitu cases. STORE describes code 0 includes cases of purely in situ carcinoma.
For the first time this month, we are making available the presentation as a PDF download if you would like to have it as a reference. Click below to download the PDF version of this month’s CTR Coding Break.
https://drive.google.com/file/d/1RKzDZvQnoRIr47jL9pMJFrbhVk4184JJ/view?usp=sharing
- published: 24 Jul 2020
- views: 2001
0:44
Vascular Invasion
Copyright 2012 Johns Hopkins University. Artwork by Bona Kim
Copyright 2012 Johns Hopkins University. Artwork by Bona Kim
https://wn.com/Vascular_Invasion
Copyright 2012 Johns Hopkins University. Artwork by Bona Kim
- published: 03 Feb 2012
- views: 4737
2:30
Lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC)
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
[email protected],
https://plus.google.com/...
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
[email protected],
https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn
,
,https://plus.google.com/u/0/+AlexandrosGSfakianakis
,
https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ
,
https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Breast Cancer Res Treat. 2018 Jan 27;:
Authors: Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F
Abstract
PURPOSE: Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC).
METHODS: The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-NAC prognostic scores (ypAJCC, RCB, CPS, CPS + EG and Neo-Bioscore) were evaluated and compared with or without the addition of LVI.
RESULTS: Out of 1033 tumors, LVI was present on surgical specimens in 29.2% and absent in 70.8% of the cases. Post-NAC LVI was associated with impaired disease-free survival (DFS) (HR 2.54; 95% CI 1.96-3.31; P 0.001), and the magnitude of this effect depended on BC subtype (Pinteraction = 0.003), (luminal BC: HR 1.83; P = 0.003; triple negative BC: HR 3.73; P 0.001; HER2-positive BC: HR 6.21; P 0.001). Post-NAC LVI was an independent predictor of local relapse, distant metastasis, and overall survival; and increased the accuracy of all five post-NAC prognostic scoring systems.
CONCLUSIONS: Post-NAC LVI is a strong independent prognostic factor that: (i) should be systematically reported in pathology reports; (ii) should be used as stratification factor after NAC to propose inclusion in second-line trials or adjuvant treatment; (iii) should be included in post-NAC scoring systems.
PMID: 29374852
- video upload powered by https://www.TunesToTube.com
https://wn.com/Lymphovascular_Invasion_(Lvi)_After_Neoadjuvant_Chemotherapy_(Nac)_For_Breast_Cancer_(Bc)
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
[email protected],
https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn
,
,https://plus.google.com/u/0/+AlexandrosGSfakianakis
,
https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ
,
https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma.
Breast Cancer Res Treat. 2018 Jan 27;:
Authors: Hamy AS, Lam GT, Laas E, Darrigues L, Balezeau T, Guerin J, Livartowski A, Sadacca B, Pierga JY, Vincent-Salomon A, Coussy F, Becette V, Bonsang-Kitzis H, Rouzier R, Feron JG, Benchimol G, Laé M, Reyal F
Abstract
PURPOSE: Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC).
METHODS: The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-NAC prognostic scores (ypAJCC, RCB, CPS, CPS + EG and Neo-Bioscore) were evaluated and compared with or without the addition of LVI.
RESULTS: Out of 1033 tumors, LVI was present on surgical specimens in 29.2% and absent in 70.8% of the cases. Post-NAC LVI was associated with impaired disease-free survival (DFS) (HR 2.54; 95% CI 1.96-3.31; P 0.001), and the magnitude of this effect depended on BC subtype (Pinteraction = 0.003), (luminal BC: HR 1.83; P = 0.003; triple negative BC: HR 3.73; P 0.001; HER2-positive BC: HR 6.21; P 0.001). Post-NAC LVI was an independent predictor of local relapse, distant metastasis, and overall survival; and increased the accuracy of all five post-NAC prognostic scoring systems.
CONCLUSIONS: Post-NAC LVI is a strong independent prognostic factor that: (i) should be systematically reported in pathology reports; (ii) should be used as stratification factor after NAC to propose inclusion in second-line trials or adjuvant treatment; (iii) should be included in post-NAC scoring systems.
PMID: 29374852
- video upload powered by https://www.TunesToTube.com
- published: 30 Jan 2018
- views: 1158
3:18
Tip-1; Lymphovascular vs. Venous Invasion
Understanding the importance of lymphovascular invasion (LVI) versus venous invasion (VI) in cancer is crucial for accurate diagnosis, staging, and treatment de...
Understanding the importance of lymphovascular invasion (LVI) versus venous invasion (VI) in cancer is crucial for accurate diagnosis, staging, and treatment decisions. LVI refers to the infiltration of cancer cells into lymphatics, which increases the risk for lymph node metastasis, while VI specifically involves tumor cells invading venous structures, so increasing the risk of hematogenous distant metastasis.
https://wn.com/Tip_1_Lymphovascular_Vs._Venous_Invasion
Understanding the importance of lymphovascular invasion (LVI) versus venous invasion (VI) in cancer is crucial for accurate diagnosis, staging, and treatment decisions. LVI refers to the infiltration of cancer cells into lymphatics, which increases the risk for lymph node metastasis, while VI specifically involves tumor cells invading venous structures, so increasing the risk of hematogenous distant metastasis.
- published: 26 Jun 2023
- views: 455
27:00
Standardising Tumour Pathology Reporting: Lymphovascular Invasion
Learn more about why we should standardize tumor pathology reporting in this webinar on Lymphovascular Invasion, presented by Drs. Luong and Salas 22 September ...
Learn more about why we should standardize tumor pathology reporting in this webinar on Lymphovascular Invasion, presented by Drs. Luong and Salas 22 September 2021. This webinar was broadcast as a part of our "Standardizing Tumor Pathology Reporting - Part 2" Series. This seminar is co-sponsored by the ACVP and the Veterinary Cancer Guidelines and Protocols group and is sure to generate some great conversation. Why do we need to standardize? How can we standardize? How can we all be a part of the conversation? What is the role of digital pathology and image analysis in standardization? Join a phenomenal panel of pathologists, clinicians, and computer scientists who are at the cutting edge of standardization.
The Davis-Thompson Foundation is a nonprofit organization for the advancement of veterinary and comparative pathology. Become a member! https://davisthompsonfoundation.org/register/individual/
Like and comment to let us know how you liked this content!
Subscribe to our channel and click on the bell button to be notified of new videos:
https://www.youtube.com/channel/UCvGM1s5wysXq-HGLAyZzClQ
Find us on the web: https://davisthompsonfoundation.org/
Follow us on Facebook: https://www.facebook.com/groups/CLDavisFoundation/
Find us on Instagram: https://www.instagram.com/davisthompsonfoundation/
#veterinarymedicine #veterinarypathology #davisthompsonfoundation #oncology #surgicalpathology #tumors
https://wn.com/Standardising_Tumour_Pathology_Reporting_Lymphovascular_Invasion
Learn more about why we should standardize tumor pathology reporting in this webinar on Lymphovascular Invasion, presented by Drs. Luong and Salas 22 September 2021. This webinar was broadcast as a part of our "Standardizing Tumor Pathology Reporting - Part 2" Series. This seminar is co-sponsored by the ACVP and the Veterinary Cancer Guidelines and Protocols group and is sure to generate some great conversation. Why do we need to standardize? How can we standardize? How can we all be a part of the conversation? What is the role of digital pathology and image analysis in standardization? Join a phenomenal panel of pathologists, clinicians, and computer scientists who are at the cutting edge of standardization.
The Davis-Thompson Foundation is a nonprofit organization for the advancement of veterinary and comparative pathology. Become a member! https://davisthompsonfoundation.org/register/individual/
Like and comment to let us know how you liked this content!
Subscribe to our channel and click on the bell button to be notified of new videos:
https://www.youtube.com/channel/UCvGM1s5wysXq-HGLAyZzClQ
Find us on the web: https://davisthompsonfoundation.org/
Follow us on Facebook: https://www.facebook.com/groups/CLDavisFoundation/
Find us on Instagram: https://www.instagram.com/davisthompsonfoundation/
#veterinarymedicine #veterinarypathology #davisthompsonfoundation #oncology #surgicalpathology #tumors
- published: 04 Oct 2021
- views: 1156
3:10
Introduction to Cancer Biology (Part 3): Tissue Invasion and Metastasis
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation p...
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation provides a closer look at how the EGFR pathway activates and modulates this process of metastasis. This animation is the third part of the series "An Introduction to Cancer Biology".
REFERENCES:
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun;36(9):1171-9.
4. Potapova O, Fakhrai H, Mercola D. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Int J Cancer. 1996 May 29;66(5):669-77.
5. Andl CD, Mizushima T, Nakagawa H, et al. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003 Jan 17;278(3):1824-30.
6. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul 10;237(4811):178-82.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995 Oct;6(10):1251-9.
8. Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer. 2001 Oct 15;94(2):185-91.
9. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003; 35(5):327-36.
10. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005 Aug 10;23(23):5386-403.
11. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005 Sep 20;23(27):6771-90.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 Oct 13;103(2):253-62.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37.
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002 Apr; 2(4):277-88.
15. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci. 2003 Dec;1010:1-8.
16. Veiby OP, Read MA. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Clin Cancer Res. 2004 May 15;10(10):3333-41.
17. Foo P. Metastasis: The journey of mobile cancer cells. Harvard Science Review. Spring 2002;30-2.
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23(5):1011-27.
19. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1007-21.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.
21. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.
https://wn.com/Introduction_To_Cancer_Biology_(Part_3)_Tissue_Invasion_And_Metastasis
Another common mechanism of cancer biology is the ability of malignant cells to migrate from their original site to organs throughout the body. This animation provides a closer look at how the EGFR pathway activates and modulates this process of metastasis. This animation is the third part of the series "An Introduction to Cancer Biology".
REFERENCES:
1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(1):57-70.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21-6.
3. Gerharz CD, Ramp U, Reinecke P, et al. Analysis of growth factor-dependent signalling in human epithelioid sarcoma cell lines. Clues to the role of autocrine, juxtacrine and paracrine interactions in epithelioid sarcoma. Eur J Cancer. 2000 Jun;36(9):1171-9.
4. Potapova O, Fakhrai H, Mercola D. Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Int J Cancer. 1996 May 29;66(5):669-77.
5. Andl CD, Mizushima T, Nakagawa H, et al. Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003 Jan 17;278(3):1824-30.
6. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987 Jul 10;237(4811):178-82.
7. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ. 1995 Oct;6(10):1251-9.
8. Egeblad M, Mortensen OH, Jaattela M. Truncated ErbB2 receptor enhances ErbB1 signaling and induces reversible, ERK-independent loss of epithelial morphology. Int J Cancer. 2001 Oct 15;94(2):185-91.
9. Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med. 2003; 35(5):327-36.
10. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005 Aug 10;23(23):5386-403.
11. Beeram M, Patnaik A, Rowinsky EK. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol. 2005 Sep 20;23(27):6771-90.
12. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000 Oct 13;103(2):253-62.
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37.
14. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002 Apr; 2(4):277-88.
15. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M. An introduction to the molecular mechanisms of apoptosis. Ann N Y Acad Sci. 2003 Dec;1010:1-8.
16. Veiby OP, Read MA. Chemoresistance: impact of nuclear factor (NF)-kappaB inhibition by small interfering RNA. Clin Cancer Res. 2004 May 15;10(10):3333-41.
17. Foo P. Metastasis: The journey of mobile cancer cells. Harvard Science Review. Spring 2002;30-2.
18. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005 Feb 10;23(5):1011-27.
19. Ellis LM. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am. 2004 Oct; 18(5):1007-21.
20. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.
21. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jan 1;24(1):16-24.
- published: 27 Oct 2012
- views: 457215
2:05
Lymphovascular invasion (LVI) and non-T4 muscular invasion (non-T4MI) significantly increased the lo
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
[email protected],
https://plus.google.com/...
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
[email protected],
https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn
,
,https://plus.google.com/u/0/+AlexandrosGSfakianakis
,
https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ
,
https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Predictors of locoregional recurrence in early stage buccal cancer with pathologically clear surgical margins and negative neck
via Acta Otorrinolaringológica Española
alertIcon.gif
Publication date: Available online 16 March 2018
Source:Acta Otorrinolaringológica Española
Author(s): Shakeel Uz Zaman, Shakil Aqil, Mohammad Ahsan Sulaiman
ObjectiveTo identify the significant predictors of locoregional recurrence in early stage squamous cell carcinoma (SCC) of buccal mucosa with pathologically clear surgical margins and negative neck.MethodSeventy-three patients who underwent per oral wide excision and supraomohyoid neck dissection for early stage buccal SCC with clear surgical margins (5mm margins each) and negative neck (N0) were included. None of the patients received postoperative radiotherapy or chemotherapy. Univariate and multivariate analyses were used to identify independent predictors of locoregional recurrence.ResultsRecurrence was observed in 22 of 73 (30%) cases. Twelve had local, seven had regional and three developed locoregional recurrences. Both univariate and multivariate analyses demonstrated that lymphovascular invasion (LVI) and non-T4 muscular invasion (non-T4MI) were independent predictors affecting locoregional control.ConclusionLymphovascular invasion (LVI) and non-T4 muscular invasion (non-T4MI) significantly increased the locoregional recurrence rate in early stage buccal SCC with clear surgical margins and negative nodal status. Adjuvant treatment with either radiation or chemoradiation should be considered when one or both of these factors present.
https://wn.com/Lymphovascular_Invasion_(Lvi)_And_Non_T4_Muscular_Invasion_(Non_T4Mi)_Significantly_Increased_The_Lo
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,
[email protected],
https://plus.google.com/communities/115462130054650919641?sqinv=VFJWaER0c2NCRl9ERzRjZWhxQmhzY09kVV84cjRn
,
,https://plus.google.com/u/0/+AlexandrosGSfakianakis
,
https://www.youtube.com/channel/UCQH21WX8Qn5YSTKrlJ3OrmQ
,
https://www.youtube.com/channel/UCTREJHxB6yt4Gaqs4-mLzDA
,
https://twitter.com/g_orl?lang=el,
https://www.instagram.com/alexandrossfakianakis/,
Predictors of locoregional recurrence in early stage buccal cancer with pathologically clear surgical margins and negative neck
via Acta Otorrinolaringológica Española
alertIcon.gif
Publication date: Available online 16 March 2018
Source:Acta Otorrinolaringológica Española
Author(s): Shakeel Uz Zaman, Shakil Aqil, Mohammad Ahsan Sulaiman
ObjectiveTo identify the significant predictors of locoregional recurrence in early stage squamous cell carcinoma (SCC) of buccal mucosa with pathologically clear surgical margins and negative neck.MethodSeventy-three patients who underwent per oral wide excision and supraomohyoid neck dissection for early stage buccal SCC with clear surgical margins (5mm margins each) and negative neck (N0) were included. None of the patients received postoperative radiotherapy or chemotherapy. Univariate and multivariate analyses were used to identify independent predictors of locoregional recurrence.ResultsRecurrence was observed in 22 of 73 (30%) cases. Twelve had local, seven had regional and three developed locoregional recurrences. Both univariate and multivariate analyses demonstrated that lymphovascular invasion (LVI) and non-T4 muscular invasion (non-T4MI) were independent predictors affecting locoregional control.ConclusionLymphovascular invasion (LVI) and non-T4 muscular invasion (non-T4MI) significantly increased the locoregional recurrence rate in early stage buccal SCC with clear surgical margins and negative nodal status. Adjuvant treatment with either radiation or chemoradiation should be considered when one or both of these factors present.
- published: 16 Mar 2018
- views: 258